Compare Ross Stores, Inc. (ROST) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Ross Stores, Inc. trades at $230.5 (market cap $72.09B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Ross Stores, Inc. is far larger — about 9.6× Spyre Therapeutics Inc. Common Stock's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ROST | SYRE | |
|---|---|---|
Market Cap | $72.09B | $7.52B |
Volume | 1,593,708 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $108.92 |
52-Week Low | $155.21 | $22.18 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $72.55B | $6.52B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $230.57, up 2.09% today, showing strong momentum with three consecutive earnings beats. The stock faces technical headwinds with a bearish signal but maintains robust fundamentals including 42.63% ROE and 10.85% net margins. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents a compelling investment case with analyst consensus target of $274.14 (19% upside) and strong institutional support. However, near-term technical weakness and competitive pressures in discount retail require monitoring. The company's consistent earnings outperformance and expanding margins support long-term growth prospects despite current market volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
